Latest filing published 01 Jul 2026 for Oruka Therapeutics, Inc., €263.7M.
Insider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Fairmount Healthcare Fund II L.P.: trading record in brief
Filings by Fairmount Healthcare Fund II L.P. span 2 companies, the busiest being Oruka Therapeutics, Inc. and Spyre Therapeutics, Inc. In total, 2 filings cover trades dated from 23 June 2026 to 1 July 2026.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
On 1 July 2026 came the latest disclosure, a transaction for €263.7M in Oruka Therapeutics, Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Fairmount Healthcare Fund II L.P.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 3,553,410 shares@ US$84.43CommonSEC144:0001104659-26-080011
1 of 1 declaration
